Argos Therapeutics Inc Sample Contracts

Argos Therapeutics Inc – RETENTION AGREEMENT (November 19th, 2018)

This Retention Agreement (the “Agreement”) is entered into as of July 20, 2018, by and between Argos Therapeutics, Inc. (the “Company”) and Jeffrey D. Abbey (“Executive”).

Argos Therapeutics Inc – RETENTION AGREEMENT (November 19th, 2018)

This Retention Agreement (the “Agreement”) is entered into as of July 20, 2018, by and between Argos Therapeutics, Inc. (the “Company”) and Charles Nicolette (“Executive”).

Argos Therapeutics Inc – RELEASE OF CLAIMS AGREEMENT (November 19th, 2018)

In exchange for the consideration set forth in the Retention Agreement dated July 20, 2018 (the “Retention Agreement”) to which this Release of Claims Agreement (the “Release Agreement”) is attached as Exhibit A, including receipt of the Initial Retention Amount (as defined therein) and eligibility to receive the Temporary Revised Salary Amount and Second Retention Amount (each as defined therein), all of which I acknowledge I would not otherwise be entitled to receive, I hereby agree as follows:

Argos Therapeutics Inc – RETENTION AGREEMENT (November 19th, 2018)

This Retention Agreement (the “Agreement”) is entered into as of July 20, 2018, by and between Argos Therapeutics, Inc. (the “Company”) and Richard D. Katz (“Executive”).

Argos Therapeutics Inc – RELEASE OF CLAIMS AGREEMENT (November 19th, 2018)

In exchange for the consideration set forth in the Retention Agreement dated July 20, 2018 (the “Retention Agreement”) to which this Release of Claims Agreement (the “Release Agreement”) is attached as Exhibit A, including receipt of the Initial Retention Amount (as defined therein) and eligibility to receive the Temporary Revised Salary Amount and Second Retention Amount (each as defined therein), all of which I acknowledge I would not otherwise be entitled to receive, I hereby agree as follows:

Argos Therapeutics Inc – ARGOS THERAPEUTICS, INC. CONSULTING AGREEMENT (November 19th, 2018)

This Consulting Agreement (this “Agreement”) is entered into as of August 29, 2018 (the “Effective Date”) by and between Argos Therapeutics, Inc. (the “Company”), and Charles Nicolette (the “Consultant”).

Argos Therapeutics Inc – RELEASE OF CLAIMS AGREEMENT (November 19th, 2018)

In exchange for the consideration set forth in the Retention Agreement dated July 20, 2018 (the “Retention Agreement”) to which this Release of Claims Agreement (the “Release Agreement”) is attached as Exhibit A, including receipt of the Initial Retention Amount (as defined therein) and eligibility to receive the Temporary Revised Salary Amount and Second Retention Amount (each as defined therein), all of which I acknowledge I would not otherwise be entitled to receive, I hereby agree as follows:

Argos Therapeutics Inc – ARGOS THERAPEUTICS, INC. CONSULTING AGREEMENT (November 19th, 2018)

This Consulting Agreement (this “Agreement”) is entered into as of August 29, 2018 (the “Effective Date”) by and between Argos Therapeutics, Inc. (the “Company”), and Richard Katz (the “Consultant”).

Argos Therapeutics Inc – ARGOS THERAPEUTICS, INC. CONSULTING AGREEMENT (November 19th, 2018)

This Consulting Agreement (this “Agreement”) is entered into as of August 29, 2018 (the “Effective Date”) by and between Argos Therapeutics, Inc. (the “Company”), and Jeffrey Abbey (the “Consultant”).

Argos Therapeutics Inc – 2-8 Tamagawa-dai Setagaya-ku Tokyo, 158-0096 JAPAN Re: Novated, Amended and Restated License Agreement Gentlemen: (May 15th, 2018)

I am writing on behalf of Argos Therapeutics, Inc. (“Argos”) with respect to the Novated, Amended and Restated License Agreement dated as of October 1, 2014, as amended (the “License Agreement”), by and among Argos, Medinet Co., Ltd. (“Medinet”), and MEDcell Co., Ltd. (“MEDcell” and together with Medinet, the “Medinet Parties”).

Argos Therapeutics Inc – Evaluation and Option Agreement for a Patent License (April 2nd, 2018)

This Evaluation and Option Agreement for a Patent License ("Agreement"), dated as of February 1, 2018 ("Effective Date"), is by and between Actigen Limited (“Patent Holder”) Pharmstandard International, S.A. ("Prospective Licensor") and Argos Therapeutics, Inc. ("Prospective Sublicensee").

Argos Therapeutics Inc – to License Agreement between Argos Therapeutics, Inc. (hereinafter “Argos”) - and - Lummy (Hong Kong) Co., Ltd. (hereinafter “China Company”) This Amendment is made as of and effective _2017-10-18__________ (“Effective Date”), contingent on the full execution of the Second Stock Purchase Agreement between China Company and Argos “Second SPA”). (April 2nd, 2018)

WHEREAS, Argos and China Company entered into a license agreement dated April 7, 2015 (the “License Agreement”), as first amended on December 5, 2016;

Argos Therapeutics Inc – to License Agreement between Argos Therapeutics, Inc. (hereinafter “Argos”) - and - Lummy (Hong Kong) Co., Ltd. (hereinafter “China Company”) This Amendment is made as of and effective March 23th, 2018 (“Effective Date”), contingent on the full execution of the Amended Second Stock Purchase Agreement between China Company and Argos “Second SPA”). (April 2nd, 2018)

WHEREAS, Argos and China Company entered into a license agreement dated April 7, 2015 (the “License Agreement”), as first amended on December 5, 2016, and amended a second time on October 19, 2017;

Argos Therapeutics Inc – ARGOS THERAPEUTICS, INC. Common Stock (par value $0.001 per share) AMENDED AND RESTATED SALES AGREEMENT (February 5th, 2018)

Reference is made to that certain Sales Agreement, dated May 8, 2015 (the “Sales Agreement”), by and between Argos Therapeutics, Inc. (the “Company”) and Cowen and Company, LLC (“Cowen”), as sales agent. The Company now intends to enter into this Amended and Restated Sales Agreement (this “Agreement”) with Cowen to amend and restate the terms of the Sales Agreement in its entirety. As such, the Company confirms with Cowen, as follows:

Argos Therapeutics Inc – CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF ARGOS THERAPEUTICS, INC. (January 30th, 2018)

ARGOS Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows:

Argos Therapeutics Inc – SATISFACTION AND RELEASE AGREEMENT (November 28th, 2017)

This SATISFACTION AND RELEASE AGREEMENT (the “Agreement”) is dated as of the 22nd day of November, 2017, by and between ARGOS THERAPEUTICS, INC., a Delaware corporation (“Argos”) and SAINT-GOBAIN PERFORMANCE PLASTICS CORPORATION, a California corporation (“SGPPL”).

Argos Therapeutics Inc – REGISTRATION RIGHTS AGREEMENT (November 28th, 2017)

This Registration Rights Agreement (this “Agreement”) is made and entered into as of November 22, 2017 by and among Argos Therapeutics, Inc., a Delaware corporation (the “Company”), and Saint-Gobain Plastics Performance Corporation, a California corporation (“Saint-Gobain”).

Argos Therapeutics Inc – SATISFACTION AND RELEASE AGREEMENT (September 25th, 2017)

This SATISFACTION AND RELEASE AGREEMENT (the “Agreement”) is dated as of the 22nd day of September, 2017, by and between ARGOS THERAPEUTICS, INC., a Delaware corporation (“Argos”) and INVETECH PTY LTD, an Australian company (“Invetech”).

Argos Therapeutics Inc – REGISTRATION RIGHTS AGREEMENT (September 25th, 2017)

This Registration Rights Agreement (this “Agreement”) is made and entered into as of September 22, 2017 by and among Argos Therapeutics, Inc., a Delaware corporation (the “Company”), and Invetech Pty Ltd (“Invetech”).

Argos Therapeutics Inc – ARGOS THERAPEUTICS, INC. 2014 STOCK INCENTIVE PLAN (August 2nd, 2017)
Argos Therapeutics Inc – NOTE PURCHASE AGREEMENT (June 16th, 2017)

This NOTE PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of June 15, 2017 by and among Argos Therapeutics, Inc., a Delaware corporation (the “Company”) and Pharmstandard International S.A. (the “Investor”).

Argos Therapeutics Inc – Argos Therapeutics Announces $6,000,000 Secured Convertible Note Financing (June 16th, 2017)

This press release does not constitute an offer to sell or the solicitation of an offer to buy the Securities, nor shall there be any sale of the Securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the Securities under the resale registration statement will only be by means of a prospectus.

Argos Therapeutics Inc – REGISTRATION RIGHTS AGREEMENT (June 16th, 2017)

This Registration Rights Agreement (this “Agreement”) is made and entered into as of June 15, 2017 by and among Argos Therapeutics, Inc., a Delaware corporation (the “Company”), and Pharmstandard International S.A. (“PHS”). Capitalized terms used herein have the respective meanings ascribed thereto in that certain Note Purchase Agreement dated as of the date hereof by and among the Company and PHS (the “Purchase Agreement”) unless otherwise defined herein.

Argos Therapeutics Inc – First Amendment (May 10th, 2017)

WHEREAS, the original License Agreement provided for technology transfer of Argos’ Automated Systems for manufacture of AGS-003 and now the parties would like to further include technology transfer of Argos’ manual method for manufacturing AGS-003 to China Company;

Argos Therapeutics Inc – LEASE TERMINATION AGREEMENT (May 10th, 2017)

THIS LEASE TERMINATION AGREEMENT (this "Agreement") is entered into effective March 31, 2017, by and between Keystone-Centennial II, LLC, a North Carolina limited liability company, ("Landlord"), and Argos Therapeutics, Inc., a Delaware corporation, ("Tenant").

Argos Therapeutics Inc – Webcast April 18, 2017 Results of February Interim Analysis of ADAPT Trial and Perspective on Decision to Keep Trial Open Any statements in this presentation about Argos' future expectations, plans and prospects, including statements about the ADAPT trial and the interim data from the trial, Argos' anticipated meeting with the FDA, clinical development of Argos' product candidates and future expectations and plans and prospects for Argos and other statements containing the words "believes," "anticipates," "estimates," "expects," "intends," "plans," "predicts," "projects," "targets," "may," "po (April 18th, 2017)
Argos Therapeutics Inc – LEASE TERM SHEET (March 16th, 2017)

THIS LEASE TERM SHEET is made a part of the attached Lease Agreement between Landlord and Tenant. Use of the following capitalized terms (indicated in bold type) in this Lease shall be deemed a reference to the information set out below.

Argos Therapeutics Inc – Confidential Materials omitted and filed separately with the Securities and Exchange Commission .Double asterisks denote omissions. (March 16th, 2017)
Argos Therapeutics Inc – SECOND AMENDMENT (March 16th, 2017)

THIS SECOND AMENDMENT TO DEVELOPMENT AGREEMENT (the “Second Amendment”) is entered into by and between SAINT-GOBAIN PERFORMANCE PLASTICS CORPORATION, a California corporation having an office at 31500 Solon Road, Solon, OH 44139 (“SGPPL”), and ARGOS THERAPEUTICS, INC., a Delaware corporation having an office at 4233 Technology Drive, Durham, NC 27704 (“Argos”). SGPPL and Argos are hereafter referred to collectively as the “Parties,” “Other Party,” or individually as a “Party”, as applicable.

Argos Therapeutics Inc – AMENDMENT NO. 3 TO FIFTH AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (March 16th, 2017)

This Amendment No. 3 (this “Amendment”) to the Fifth Amended and Restated Registration Rights Agreement, dated August 9, 2013 (the “Registration Rights Agreement”), by and among the Company and the Holders (as defined therein) is entered into as of the 6th day of March, 2017 by and among Argos Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the signatories hereto. Capitalized terms not defined herein shall have the meanings given to such terms in the Registration Rights Agreement.

Argos Therapeutics Inc – Contract (March 6th, 2017)

THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, OR (iii) RECEIPT OF NO ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES REASONABLY SATISFACTORY TO THE COMPANY, AND WITHOUT OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THIS WARRANT.

Argos Therapeutics Inc – Contract (March 6th, 2017)

THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, OR (iii) RECEIPT OF NO ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES REASONABLY SATISFACTORY TO THE COMPANY, AND WITHOUT OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THIS WARRANT.

Argos Therapeutics Inc – Contract (March 6th, 2017)

THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, OR (iii) RECEIPT OF NO ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES REASONABLY SATISFACTORY TO THE COMPANY, AND WITHOUT OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THIS WARRANT.

Argos Therapeutics Inc – Argos Therapeutics Completes Lease Agreement for Commercial Manufacturing Space on the Centennial Campus of North Carolina State University 40,000 square feet of newly constructed space at the Center for Technology & Innovation to support initial commercialization of company’s individualized immunotherapies (January 23rd, 2017)

DURHAM, N.C., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, announced today the completion of a lease agreement with Keystone-Centennial II, LLC, for 40,000 square feet of newly constructed manufacturing space at the Center for Technology & Innovation (CTI) on the Centennial Campus of North Carolina State University in Raleigh, NC.

Argos Therapeutics Inc – Form of Senior Note (FACE OF SECURITY) (January 9th, 2017)

UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY. UNLESS THIS SECURITY IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY SECURITY ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER